ARVN – arvinas, inc. (US:NASDAQ)
Stock Stats
News
Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation [Yahoo! Finance]
Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases
Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at Morgan Stanley from $48.00 to $12.00. They now have an "equal weight" rating on the stock.
Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at Guggenheim from $57.00 to $32.00. They now have a "buy" rating on the stock.
Form 8-K ARVINAS, INC. For: Apr 04
Form 4 ARVINAS, INC. For: Mar 18 Filed by: Berkowitz Noah
Form 144 ARVINAS, INC. Filed by: Berkowitz Noah
Form 8-K ARVINAS, INC. For: Mar 11
Form 4 ARVINAS, INC. For: Feb 24 Filed by: Loomis David K
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.